References

Long-term results with immediate androgen suppression and external irradiation in patients with locally advance prostate cancer (an EORTC study): A phase III randomized trial

10.1016/s0140-6736(02)09408-4 · 2002 · External reference

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer

10.1001/jama.292.7.821 · 2004 · External reference

Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

10.1200/jco.2007.14.9021 · 2008 · External reference

High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients

10.1016/s0360-3016(02)02857-2 · 2002 · External reference

Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials

10.1016/j.ijrobp.2008.10.091 · 2009 · External reference

A randomized trial of 79.2 Gy versus 70.2 Gy radiation therapy (RT) for localized prostate cancer [Abstract]

2015 · External reference

Risk of fracture after androgen deprivation for prostate cancer

10.1056/nejmoa041943 · 2005 · External reference

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

10.1200/jco.2006.06.2497 · 2006 · External reference

High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes

10.1016/j.ijrobp.2011.10.036 · 2012 · External reference

Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?

10.1016/j.ijrobp.2012.06.030 · 2013 · External reference

Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06

10.1016/j.ijrobp.2010.01.009 · 2011 · External reference

Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer

10.1016/j.ijrobp.2010.04.004 · 2011 · External reference

Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial [Abstract]

10.1200/jco.2011.29.15_suppl.4521 · 2011 · External reference

A phase III trial of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy [Abstract]

2015 · External reference

NCCN clinical practice guidelines in oncology: prostate cancer

10.6004/jnccn.2010.0012 · 2010 · External reference

Outcomes of high-dose intensity-modulated radiotherapy alone with 1 cm planning target volume posterior margin for localized prostate cancer

10.1186/1748-717x-8-285 · 2013 · External reference

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

10.1016/j.ijrobp.2006.04.029 · 2006 · External reference

The role of conceptual frameworks in epidemiological analysis: a hierarchical approach

10.1093/ije/26.1.224 · 1997 · External reference

A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy

10.1016/j.eururo.2013.03.033 · 2013 · External reference

Recurrence-free survival rates after external beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect?

10.1002/cncr.20093 · 2004 · External reference

High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): A randomized, controlled, phase III trial

10.1016/s1470-2045(15)70045-8 · 2015 · External reference

Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcome

10.1016/s0090-4295(99)80019-3 · 1995 · External reference

Perineural invasion in cancer: A review of the literature

10.1002/cncr.24396 · 2009 · External reference

Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy

10.1002/(sici)1097-0142(19970101)79:1<75::aid-cncr11>3.0.co;2-3 · 1997 · External reference